Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects

Trial Profile

Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Durvalumab (Primary) ; Olaparib (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms MoST Addendum 3
  • Most Recent Events

    • 20 Jul 2017 The two ANZCTR records (ACTRN12616000931471, ACTRN12617001000392 & ACTRN12616001019493p) has same secondary identifier U1111-1182-6652. Therefore, check carefully while updating against ANZCTR incomings
    • 19 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top